ACTG 260: A randomized, phase I-II, dose-ranging trial of the anti- human immunodeficiency virus activity of delavirdine monotherapy

Michael F. Para, Patricia Meehan, Jeanne Holden-Wiltse, Margaret A Fischl, Gene Morse, Robert Shafer, Lisa M. Demeter, Kenneth Wood, Tom Nevin, Nzeera Virani-Ketter, William W. Freimuth

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

ACTG 260 was an open-label, four-arm trial designed to study the safety and anti-human immunodeficiency virus (anti-HIV) activity of delavirdine monotherapy at three ranges of concentrations in plasma compared to those of control therapy with zidovudine or didanosine. Delavirdine doses were adjusted weekly until subjects were within their target trough concentration range (3 to 10, 11 to 30, or 31 to 50 μM). A total of 113 subjects were analyzed. At week 2, the mean HIV type 1 (HIV-1) RNA level declines among the subjects in the three delavirdine arms were similar (0.87, 1.08, and 1.02 log10 for the low, middle, and high target arms, respectively), but by week 8, the subjects in the pooled delavirdine arms showed only a 0.10 log10 reduction. In the subjects in the nucleoside arm, mean HIV-1 RNA level reductions at weeks 2 and 8 were 0.67 and 0.55 log10, respectively. Because viral suppression by delavirdine was not maintained, the trial was stopped early. Rash, which was usually self-limited, developed in 36% of subjects who received delavirdine. Delavirdine monotherapy has potent anti-HIV activity at 2 weeks, but its activity is time limited due to the rapid emergence of drug resistance.

Original languageEnglish
Pages (from-to)1373-1378
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume43
Issue number6
StatePublished - Jun 1 1999

Fingerprint

Delavirdine
HIV
HIV-1
RNA
Didanosine
Zidovudine
Exanthema
Nucleosides
Drug Resistance
Safety

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

ACTG 260 : A randomized, phase I-II, dose-ranging trial of the anti- human immunodeficiency virus activity of delavirdine monotherapy. / Para, Michael F.; Meehan, Patricia; Holden-Wiltse, Jeanne; Fischl, Margaret A; Morse, Gene; Shafer, Robert; Demeter, Lisa M.; Wood, Kenneth; Nevin, Tom; Virani-Ketter, Nzeera; Freimuth, William W.

In: Antimicrobial Agents and Chemotherapy, Vol. 43, No. 6, 01.06.1999, p. 1373-1378.

Research output: Contribution to journalArticle

Para, MF, Meehan, P, Holden-Wiltse, J, Fischl, MA, Morse, G, Shafer, R, Demeter, LM, Wood, K, Nevin, T, Virani-Ketter, N & Freimuth, WW 1999, 'ACTG 260: A randomized, phase I-II, dose-ranging trial of the anti- human immunodeficiency virus activity of delavirdine monotherapy', Antimicrobial Agents and Chemotherapy, vol. 43, no. 6, pp. 1373-1378.
Para, Michael F. ; Meehan, Patricia ; Holden-Wiltse, Jeanne ; Fischl, Margaret A ; Morse, Gene ; Shafer, Robert ; Demeter, Lisa M. ; Wood, Kenneth ; Nevin, Tom ; Virani-Ketter, Nzeera ; Freimuth, William W. / ACTG 260 : A randomized, phase I-II, dose-ranging trial of the anti- human immunodeficiency virus activity of delavirdine monotherapy. In: Antimicrobial Agents and Chemotherapy. 1999 ; Vol. 43, No. 6. pp. 1373-1378.
@article{92ddd34d3153402ca7c9989a3969b5b2,
title = "ACTG 260: A randomized, phase I-II, dose-ranging trial of the anti- human immunodeficiency virus activity of delavirdine monotherapy",
abstract = "ACTG 260 was an open-label, four-arm trial designed to study the safety and anti-human immunodeficiency virus (anti-HIV) activity of delavirdine monotherapy at three ranges of concentrations in plasma compared to those of control therapy with zidovudine or didanosine. Delavirdine doses were adjusted weekly until subjects were within their target trough concentration range (3 to 10, 11 to 30, or 31 to 50 μM). A total of 113 subjects were analyzed. At week 2, the mean HIV type 1 (HIV-1) RNA level declines among the subjects in the three delavirdine arms were similar (0.87, 1.08, and 1.02 log10 for the low, middle, and high target arms, respectively), but by week 8, the subjects in the pooled delavirdine arms showed only a 0.10 log10 reduction. In the subjects in the nucleoside arm, mean HIV-1 RNA level reductions at weeks 2 and 8 were 0.67 and 0.55 log10, respectively. Because viral suppression by delavirdine was not maintained, the trial was stopped early. Rash, which was usually self-limited, developed in 36{\%} of subjects who received delavirdine. Delavirdine monotherapy has potent anti-HIV activity at 2 weeks, but its activity is time limited due to the rapid emergence of drug resistance.",
author = "Para, {Michael F.} and Patricia Meehan and Jeanne Holden-Wiltse and Fischl, {Margaret A} and Gene Morse and Robert Shafer and Demeter, {Lisa M.} and Kenneth Wood and Tom Nevin and Nzeera Virani-Ketter and Freimuth, {William W.}",
year = "1999",
month = "6",
day = "1",
language = "English",
volume = "43",
pages = "1373--1378",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - ACTG 260

T2 - A randomized, phase I-II, dose-ranging trial of the anti- human immunodeficiency virus activity of delavirdine monotherapy

AU - Para, Michael F.

AU - Meehan, Patricia

AU - Holden-Wiltse, Jeanne

AU - Fischl, Margaret A

AU - Morse, Gene

AU - Shafer, Robert

AU - Demeter, Lisa M.

AU - Wood, Kenneth

AU - Nevin, Tom

AU - Virani-Ketter, Nzeera

AU - Freimuth, William W.

PY - 1999/6/1

Y1 - 1999/6/1

N2 - ACTG 260 was an open-label, four-arm trial designed to study the safety and anti-human immunodeficiency virus (anti-HIV) activity of delavirdine monotherapy at three ranges of concentrations in plasma compared to those of control therapy with zidovudine or didanosine. Delavirdine doses were adjusted weekly until subjects were within their target trough concentration range (3 to 10, 11 to 30, or 31 to 50 μM). A total of 113 subjects were analyzed. At week 2, the mean HIV type 1 (HIV-1) RNA level declines among the subjects in the three delavirdine arms were similar (0.87, 1.08, and 1.02 log10 for the low, middle, and high target arms, respectively), but by week 8, the subjects in the pooled delavirdine arms showed only a 0.10 log10 reduction. In the subjects in the nucleoside arm, mean HIV-1 RNA level reductions at weeks 2 and 8 were 0.67 and 0.55 log10, respectively. Because viral suppression by delavirdine was not maintained, the trial was stopped early. Rash, which was usually self-limited, developed in 36% of subjects who received delavirdine. Delavirdine monotherapy has potent anti-HIV activity at 2 weeks, but its activity is time limited due to the rapid emergence of drug resistance.

AB - ACTG 260 was an open-label, four-arm trial designed to study the safety and anti-human immunodeficiency virus (anti-HIV) activity of delavirdine monotherapy at three ranges of concentrations in plasma compared to those of control therapy with zidovudine or didanosine. Delavirdine doses were adjusted weekly until subjects were within their target trough concentration range (3 to 10, 11 to 30, or 31 to 50 μM). A total of 113 subjects were analyzed. At week 2, the mean HIV type 1 (HIV-1) RNA level declines among the subjects in the three delavirdine arms were similar (0.87, 1.08, and 1.02 log10 for the low, middle, and high target arms, respectively), but by week 8, the subjects in the pooled delavirdine arms showed only a 0.10 log10 reduction. In the subjects in the nucleoside arm, mean HIV-1 RNA level reductions at weeks 2 and 8 were 0.67 and 0.55 log10, respectively. Because viral suppression by delavirdine was not maintained, the trial was stopped early. Rash, which was usually self-limited, developed in 36% of subjects who received delavirdine. Delavirdine monotherapy has potent anti-HIV activity at 2 weeks, but its activity is time limited due to the rapid emergence of drug resistance.

UR - http://www.scopus.com/inward/record.url?scp=0033063976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033063976&partnerID=8YFLogxK

M3 - Article

C2 - 10348755

AN - SCOPUS:0033063976

VL - 43

SP - 1373

EP - 1378

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -